Arnold Lippa - RespireRx Pharmaceuticals Executive Chairman and Chief Scientific Officer
| RSPIDelisted Stock | USD 0.01 0.00 0.00% |
Chairman
Dr. Arnold S. Lippa, Ph.D is the Executive Chairman of the Board, Chief Scientific Officer of the Company. He previously served as Chairman of the Board, President, Chief Executive Officer of the company. Dr. Lippa is a Senior Managing Director and founder of T Morgen Capital LLC through which he administers his familys assets. T Morgen Capital LLC is a significant equity owner and managing member of Aurora Capital LLC, a boutique investment bank and securities firm of which Mr. Margolis is the president and founder, which has served as a placement agent with respect to the Companys recent financings. Dr. Lippa and Mr. Margolis jointly manage, since 2004, Atypical BioCapital Management LLC and Atypical BioVentures Fund LLC, a life sciences fund management company and venture fund, respectively. Since 2006, Dr. Lippa has also been the Executive Chairman of the board of Xintria Pharmaceutical Corporationrationration, a Delaware corporation, as well as a member of its board of directors. Dr. Lippa was cofounder of DOV Pharmaceutical, Inc., where he served as Chairman of the Board and Chief Executive Officer from its inception in 1995 through 2005. Dr. Lippa stepped down as a director of DOV Pharmaceuticals, Inc. in 2006. since 2015.
| Age | 76 |
| Tenure | 10 years |
| Phone | 201 444 4947 |
| Web | https://www.respirerx.com |
RespireRx Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (8.3401) % which means that it has lost $8.3401 on every $100 spent on assets. This is way below average. RespireRx Pharmaceuticals' management efficiency ratios could be used to measure how well RespireRx Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.RespireRx Pharmaceuticals currently holds 2.42 M in liabilities. RespireRx Pharmaceuticals has a current ratio of 0.01, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist RespireRx Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, RespireRx Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like RespireRx Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for RespireRx to invest in growth at high rates of return. When we think about RespireRx Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 2 records | CHAIRMAN Age | ||
| Eric Weisblum | Silo Pharma | 54 | |
| Garo Armen | Protagenic Therapeutics | 72 | |
Management Performance
| Return On Asset | -8.34 |
RespireRx Pharmaceuticals Leadership Team
Elected by the shareholders, the RespireRx Pharmaceuticals' board of directors comprises two types of representatives: RespireRx Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of RespireRx. The board's role is to monitor RespireRx Pharmaceuticals' management team and ensure that shareholders' interests are well served. RespireRx Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, RespireRx Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jeff Margolis, VP, Treasurer, Secretary and Director | ||
| Richard Purcell, Senior Vice President - Research and Development | ||
| Arvid Carlsson, Consultant | ||
| David Dickason, VP Devel | ||
| Arnold Lippa, Executive Chairman and Chief Scientific Officer | ||
| Marc Radin, Controller |
RespireRx Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is RespireRx Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Currently Active Assets on Macroaxis
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Stocks Directory module to find actively traded stocks across global markets.
Other Consideration for investing in RespireRx Pink Sheet
If you are still planning to invest in RespireRx Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the RespireRx Pharmaceuticals' history and understand the potential risks before investing.
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Stocks Directory Find actively traded stocks across global markets |